CliffBio
small molecule

TREANDA

BENDAMUSTINE HYDROCHLORIDE

Loss of exclusivityMarch 2030latest FDA-listed patent expiry
CompanyCephalon →View the full company profile on CliffBio

Drug detail

Brand nameTREANDA
Active ingredientBENDAMUSTINE HYDROCHLORIDE
Strength180MG/2ML (90MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalSeptember 2013
Marketing statusDISCN

Listed patents

PatentExpiresType
8344006*PEDMarch 2030—
8445524*PEDSeptember 2029—
8344006September 2029product
8445524March 2029substance
8791270*PEDJuly 2026—
8791270January 2026product

More from Cephalon

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TREANDA patent cliff — loss of exclusivity March 2030 | CliffBio